Cytek Biosciences, Inc. (CTKB) Stock Score, Valuation & Financial Research
Cytek Biosciences, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for CTKB
Cytek Biosciences, Inc. currently has a Wall Street Score of 24/100. The stored market price is $4.93. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Cytek Biosciences, Inc. does
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a
CTKB financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $4.93
- Market capitalization:
- $636.7M
- Revenue:
- $206.7M
- Net income:
- $-80.6M
- Free cash flow:
- $-8.8M
- Cash:
- $73.8M
- Total debt:
- $26.5M
- EPS:
- -0.62
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 8/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-8.8M, showing cash burn in the current stored period.
- The balance sheet shows $73.8M of cash versus $26.5M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.2 points: CTKB decreased 0.2 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CTKB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.